Related Experiment Video
Updated: Nov 9, 2025
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Prevalence, Mechanisms, and Management of Ischemic Stroke in Heart Failure Patients
1Department of Neurology, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas.
Insights
Heart failure (HF) increases stroke risk, even without atrial fibrillation (AF). Identifying high-risk HF patients may guide anticoagulation therapy for better stroke prevention.
Area of Science:
- Cardiology
- Neurology
- Thrombosis Research
Background:
- Heart failure (HF) and stroke are leading causes of mortality.
- Atrial fibrillation (AF) is a known stroke risk in HF patients, but HF itself independently elevates stroke risk.
- Thromboembolism is the primary mechanism for stroke in HF.
Purpose of the Study:
- To explore stroke risk in HF patients independent of AF.
- To evaluate the efficacy of anticoagulation in HF patients at high risk for stroke.
- To discuss the role of novel oral anticoagulants in managing stroke risk in HF.
Main Methods:
- Review of existing evidence on stroke risk in HF.
- Analysis of stroke-risk prediction models for HF patients.
- Comparison of warfarin with non-vitamin K oral anticoagulants (NOACs).
Main Results:
- HF increases stroke risk independently of AF, primarily via thromboembolism.
- Warfarin has shown limited benefit in HF patients without AF due to bleeding risks.
- Emerging evidence suggests specific HF patient subgroups may benefit from anticoagulation.
Conclusions:
- Identifying high-risk HF patients is crucial for targeted stroke prevention.
- Non-vitamin K oral anticoagulants offer a potentially better risk-benefit profile than warfarin.
- Future research should focus on patient selection and optimal antithrombotic strategies for HF management.
Abstract:
Heart failure (HF) and stroke, two of the major causes of death worldwide, are closely associated. Although atrial fibrillation (AF), which occurs in more than half of patients with HF, is a major risk factor for stroke, there is a great deal of evidence that HF itself increases the risk of stroke independent of AF. The main mechanism of stroke appears to be thromboembolism. However, previous studies have failed to demonstrate the benefit of warfarin in patients with HF without AF, as the benefit of stroke prevention was counteracted by the increased incidence of major bleeding. Recently, researchers have identified patients with HF at a particularly high risk for stroke who may benefit from anticoagulation therapy. Based on stroke-risk prediction models, it may be possible to make better stroke prevention decisions for patients with HF. Moreover, non-vitamin K oral anticoagulants have emerged as anticoagulants with a more favorable risk-benefit profile than warfarin. Future studies on selecting high-risk patients and using more appropriate antithrombotics will lead to improved management of patients with HF.
Related Concept Videos
01:30Heart Failure V: Medical Management
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:27Heart Failure I: Introduction
01:17Pathophysiology of Heart Failure
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure VII: Nursing Interventions